Breast Biopsy: Image-Guided Techniques, Reporting, and Results — Cost, Top Hospitals & Success Rates | MyMedicPlus

A breast biopsy is the definitive step in the triple-assessment pathway — the internationally accepted diagnostic framework that combines clinical examination, imaging (mammography and/or ultrasound), and histopathological tissue sampling. Pathological confirmation is mandatory before any surgical or systemic treatment is initiated for a suspected breast malignancy. Biopsy retrieves cellular or tissue material from a breast lesion for histological or cytological analysis, enabling accurate diagnosis, histological grading, and receptor-status profiling that directly determine oncological management.

Breast biopsy is not a single technique. It spans a spectrum from minimally invasive fine-needle aspiration cytology (FNAC) performed in an outpatient setting, through image-guided core needle biopsy (CNB) which is the current standard of care, to vacuum-assisted biopsy (VAB) for microcalcifications, and MRI-guided or stereotactic platforms for non-palpable lesions invisible on ultrasound. The choice of technique depends on lesion type, imaging characteristics, BI-RADS category, and whether histological architecture (rather than cytology alone) is required for receptor profiling.

Concordance between imaging findings and pathological result — known as triple-assessment concordance — must be formally assessed at multidisciplinary team (MDT) discussion. A discordant result (e.g., imaging strongly suspicious but biopsy benign) mandates repeat sampling or surgical excision. A radio-opaque titanium clip is routinely placed at the biopsy site at the time of CNB or VAB to mark the lesion for subsequent wire-localisation or seed-guided surgical excision, particularly when neoadjuvant chemotherapy is planned and may render the tumour impalpable or invisible on imaging.

Pathological reporting follows the WHO/NHSBSP five-category classification (B1-B5), which guides clinical decision-making: B1 (normal/insufficient), B2 (benign), B3 (uncertain malignant potential), B4 (suspicious), and B5 (malignant). Each category carries a specific management algorithm agreed upon by the MDT.

Breast biopsy is indicated whenever imaging or clinical findings require histopathological clarification. The following findings prompt biopsy referral:

• Suspicious breast mass on imaging (BI-RADS 4 or 5): Any solid lesion with irregular margins, spiculation, posterior acoustic shadowing, or associated calcifications on ultrasound or mammography.
• Microcalcifications: Clustered, pleomorphic, or linear-branching calcifications on mammography — require stereotactic or VAB to exclude DCIS or invasive carcinoma.
• Nipple discharge: Unilateral, spontaneous, blood-stained or serous discharge from a single duct — ductoscopy or periareolar excision with biopsy.
• Skin and nipple changes: Peau d'orange, nipple inversion, eczematoid change (Paget's disease of the nipple — requires nipple skin punch biopsy), or inflammatory changes.
• Axillary lymphadenopathy without identifiable primary: Ultrasound-guided CNB of lymph node to establish diagnosis and guide axillary staging.
• Post-treatment surveillance: Biopsy of suspicious recurrence or residual disease after neoadjuvant chemotherapy at the clipped site.
• High-risk surveillance: BI-RADS 3 lesions in BRCA1/2 mutation carriers or women with prior atypical ductal hyperplasia (ADH) or lobular carcinoma in situ (LCIS) may be biopsied on patient preference or institutional protocol.
• Discordant imaging-pathology at prior biopsy: Upgrade procedure required when prior B2 result is inconsistent with imaging suspicion.

Almost any patient with a BI-RADS 4 or 5 lesion is a candidate for image-guided breast biopsy; contraindications are rare. Pre-procedure assessment includes the following steps:

BI-RADS Category: Biopsy is recommended for BI-RADS 4 (suspicious, 2-95% malignancy risk) and BI-RADS 5 (highly suspicious, >95% malignancy risk). BI-RADS 3 (probably benign, <2% malignancy risk) is managed by 6-monthly surveillance imaging in most women; biopsy is offered in high-risk individuals or on patient request.

Coagulation and Antiplatelet Management: International guidelines recommend a pre-biopsy INR/PT check if the patient is on warfarin (target INR <1.5 for transbronchial procedures; breast CNB is generally safe with INR up to 1.5-2.0). Low-dose aspirin (75-100mg) is typically continued as the bleeding risk from CNB is low. Clopidogrel, ticagrelor, or NOACs should be reviewed in consultation with the prescribing physician — most are withheld 5-7 days before VAB, which carries a higher bleeding risk. Patients with thrombocytopenia (platelets <50 × 10⁹/L) require haematology review.

MRI-specific eligibility: Patients requiring MRI-guided biopsy must be MRI-compatible (no ferromagnetic implants), not claustrophobic, and able to tolerate gadolinium contrast (eGFR >30 mL/min required).

Informed consent: Patients must be counselled on the procedure type, imaging modality used, possibility of clip placement, risk of inadequate sampling (particularly with FNAC), post-procedure haematoma, and the requirement for a few days of restricted activity. Local anaesthetic (2% lignocaine) is used routinely; sedation or general anaesthesia is not required for CNB or FNAC.

The selection of biopsy technique is guided by lesion type, imaging modality available, and the need for histological (vs cytological) diagnosis:

1. Fine Needle Aspiration Cytology (FNAC): A 22-25G needle is inserted into the lesion (palpation-guided or ultrasound-guided) with multiple passes to aspirate cells for cytological analysis. Results available within 24-48 hours, or immediately with rapid on-site evaluation (ROSE). Sensitivity 70-80%; inadequacy rate 10-15%. Does not provide tissue architecture, histological grade, or receptor status — clinical use is now largely limited to cyst aspiration and lymph node sampling.

2. Core Needle Biopsy (CNB) — Current Standard of Care: A 14-gauge spring-loaded Tru-Cut or automated core needle acquires 3-6 tissue cores under real-time ultrasound guidance (or mammographic guidance for non-ultrasound-visible lesions). Sensitivity >95%, specificity >98%. Provides full histological diagnosis including Elston-Ellis histological grade, ER/PR/HER2 expression by immunohistochemistry, Ki-67 proliferation index, and lymphovascular invasion status. A radio-opaque titanium clip is deployed at the end of the procedure to mark the lesion site.

3. Vacuum-Assisted Biopsy (VAB): A 7-11G Mammotome or EnCor device uses vacuum suction to acquire multiple larger contiguous specimens via a single needle insertion. Preferred for: (a) mammographic microcalcifications (stereotactic VAB — post-procedure specimen X-ray confirms calcification retrieval); (b) MRI-detected lesions requiring MRI-guided sampling; (c) upgrading B3 lesions (e.g., ADH, papilloma) via complete excision VAB. Substantially lower re-excision rate than CNB for microcalcifications.

4. Stereotactic Core/Vacuum Biopsy: Digital stereotactic table positions patient prone; paired stereotactic images localise the lesion in 3D. Used specifically for calcifications not visible on ultrasound. Specimen radiograph after biopsy confirms adequate calcification sampling.

5. MRI-Guided Biopsy: For MRI-detected lesions (BPE-obscured, post-gadolinium enhancement only) with no second-look ultrasound correlate. Dedicated breast MRI coil and grid system used. Technically demanding; available at specialist centres only.

6. Wire-Localisation Excision / Vacuum-Assisted Excision: When prior biopsy is non-diagnostic or imaging-pathology discordant, surgical excision preceded by wire, radioactive seed (RSL), or radar reflector (Magseed/Savi Scout) localisation is performed. This provides definitive diagnosis and can be curative for small benign lesions.

7. Sentinel Lymph Node Biopsy (SLNB): Axillary staging procedure performed at the time of definitive surgery. Radioisotope (Tc-99m nanocolloid) and/or patent blue dye injected peri-tumourally; gamma probe or blue-staining identifies sentinel node(s) for histopathological examination, avoiding full axillary clearance in node-negative disease.

Breast biopsy provides diagnostic certainty that guides all subsequent management decisions. Key benefits include:

• Definitive tissue diagnosis: Distinguishes benign from malignant disease with >95% accuracy (CNB), avoiding unnecessary surgery for 70-80% of biopsied lesions that prove benign.
• Histological grading and molecular profiling: CNB provides Nottingham histological grade (Grade 1-3), ER/PR receptor status, HER2 amplification status (IHC ± FISH), and Ki-67 — all mandatory for oncological treatment planning including chemotherapy, endocrine therapy, and HER2-directed therapy.
• Enables neoadjuvant therapy planning: Definitive pathological diagnosis before surgery allows administration of neoadjuvant chemotherapy (NACT) or endocrine therapy, potentially enabling breast-conserving surgery (BCS) in cases initially requiring mastectomy. pCR (pathological complete response) after NACT is a strong prognosticator.
• Clip placement for surgical localisation: Allows precise surgical removal of non-palpable lesions after NACT with radiological localisation techniques.
• Minimally invasive with rapid recovery: Core needle biopsy is a day-case procedure; patients resume normal activities within 24-48 hours, with avoidance of strenuous activity for 48 hours.
• Avoids upfront surgery: In the pre-CNB era, diagnostic surgery was required for all suspicious lesions. Image-guided biopsy has reduced the number of unnecessary benign surgical excisions by over 50%.

Breast biopsy is a safe procedure; serious complications are rare. The following adverse effects may occur:

• Haematoma and bruising: The most common complication, occurring in 1-3% of CNB procedures. Usually self-limiting. Direct pressure is applied for 5-10 minutes post-procedure; ice packs reduce swelling. Large haematomas requiring drainage are uncommon (<0.5%).
• Infection: Post-biopsy abscess occurs in <1% of patients. Clean technique and single-use needles minimise risk. If infection occurs, oral antibiotics and, if necessary, aspiration or drainage are administered.
• Inadequate sampling: FNAC has an inadequacy rate of 10-15%, requiring repeat sampling. CNB inadequacy is rare (<2%) when a minimum of four adequate cores are obtained. Re-biopsy is required if the sample is insufficient for diagnosis.
• Vasovagal episode: Transient faintness and bradycardia during or immediately after the procedure due to anxiety or pain; managed by supine positioning, fluids, and reassurance. Atropine is rarely required.
• Sampling error from heterogeneous tumours: Large or morphologically heterogeneous tumours may have regions that are not sampled, leading to undergrading or missing a higher-grade component. This is relevant for neoadjuvant therapy decisions.
• Clip migration: The deployed titanium clip may migrate slightly from its original position, usually within 1-2 cm; noted and accounted for at pre-surgical localisation imaging.
• Pneumothorax (rare): Extremely rare (<0.1%) with deep posterior lesions when the needle trajectory approaches the pleura. Standard CNB should use short-throw needles (15mm excursion) to avoid pleural transgression.

All breast biopsy results should be reported using the standardised WHO/NHSBSP five-category (B1-B5) classification and discussed at a formal multidisciplinary team (MDT) meeting:

• B1 — Normal/Insufficient: Sample is inadequate or contains normal breast parenchyma only. Repeat biopsy is required if clinical or imaging suspicion persists. A minimum of four adequate cores reduces this rate to <2%.
• B2 — Benign: Fibroadenoma, fibrocystic change, fat necrosis, sclerosing adenosis. Consistent with imaging (concordant) — no further biopsy required; imaging follow-up may be recommended for complex lesions.
• B3 — Uncertain Malignant Potential (UMP): Includes atypical ductal hyperplasia (ADH — malignant upgrade rate 20-30% at surgical excision), flat epithelial atypia (FEA), lobular neoplasia (ALH/LCIS), papilloma with atypia, and radial scar. MDT discussion required; options include complete vacuum-assisted excision or intensified surveillance. ADH mandates surgical excision or complete VAB given the high upgrade rate.
• B4 — Suspicious: Features highly suspicious for malignancy but not sufficient for definitive B5 diagnosis. Usually proceeds directly to surgical excision for definitive histology.
• B5 — Malignant: B5a (DCIS in situ), B5b (invasive carcinoma), B5c (uncertain invasive or in situ), B5d (malignant lymphoma). MDT planning for surgery, neoadjuvant therapy, sentinel node biopsy, and systemic treatment commences immediately.

Triple-assessment concordance is mandatory: if imaging is strongly suspicious (BI-RADS 5) but biopsy returns B2, the result is discordant — re-biopsy or surgical excision is required regardless of the benign pathology. Full receptor profiling (ER, PR, HER2, Ki-67) is reported on all B5b specimens within 5-10 working days.

The cost of breast biopsy varies substantially depending on the technique, imaging guidance modality, pathological testing requirements, and geographic location:

• Technique cost hierarchy (lowest to highest): FNAC < ultrasound-guided CNB < stereotactic CNB < vacuum-assisted biopsy (VAB) < MRI-guided VAB < wire-localisation surgical excision.
• Imaging guidance: Ultrasound-guided CNB is the least expensive image-guided technique. Stereotactic and MRI-guided procedures require specialised equipment and add significantly to cost.
• Pathological testing: Routine H&E histology is included in the base CNB cost. Immunohistochemistry (IHC) for ER, PR, HER2 adds USD 100-400. HER2 FISH/CISH adds a further USD 200-500. Ki-67 and other markers add incrementally.
• International pricing (approximate total including consultation and pathology):
  • India: FNAC USD 20-60; CNB USD 100-300; VAB USD 300-700; MRI-guided USD 500-1,200
  • Thailand/Malaysia: CNB USD 200-500; VAB USD 500-1,000
  • UAE/Turkey: CNB USD 400-900
  • UK (NHS — no out-of-pocket cost; private USD 600-1,500 for CNB)
  • USA: CNB USD 1,500-5,000; stereotactic VAB USD 3,000-8,000
• Clip placement adds minimal cost (USD 30-100 for the clip).

In a small number of clinical scenarios, alternative approaches to immediate tissue biopsy may be considered:

1. Short-Interval Imaging Surveillance (BI-RADS 3): Lesions with a <2% malignancy risk (e.g., well-defined oval solid mass with circumscribed margins, probable fibroadenoma) may be followed with 6-monthly ultrasound for 2 years. If stable at 2 years with no change in morphology, lesion is upgraded to BI-RADS 2 and surveillance discontinued. Not appropriate for high-risk women (BRCA carriers, prior ADH/LCIS) or at patient preference.

2. Surgical Excision as Primary Diagnostic and Therapeutic Procedure: Wire-localisation excision biopsy was the historical standard before image-guided CNB became available. Still indicated for: non-diagnostic prior CNB (despite repeat attempt), discordant triple assessment, B3 lesions requiring complete excision (ADH, papilloma with atypia), and patient refusal of percutaneous biopsy. Disadvantage is that upfront surgery may not be curative (inadequate margins) requiring re-excision.

3. Liquid Biopsy: Detection of circulating tumour DNA (ctDNA) in peripheral blood — currently investigational for primary screening. Not validated as a replacement for tissue biopsy in symptomatic patients. May have future utility in monitoring treatment response and detecting early relapse.

4. Molecular Breast Imaging (MBI) / Contrast-Enhanced Mammography (CEM): These enhanced imaging modalities can refine BI-RADS categorisation and potentially reduce unnecessary biopsies of BI-RADS 4A lesions (low suspicion), but they are adjuncts to — not replacements for — histopathological diagnosis when suspicion persists.